Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says

 
• By Sue Sutter
  
Sun and clouds
The gastric cancer treatment landscape has brightened, putting a cloud over Keytruda’s accelerated approval for third-line use. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers